PMID- 25767155
OWN - NLM
STAT- MEDLINE
DCOM- 20151002
LR  - 20150716
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 54
IP  - 8
DP  - 2015 Aug
TI  - Drug survival of anti-tumour necrosis factor alpha therapy in spondyloarthropathies: 
      results from the Spanish emAR II Study.
PG  - 1459-63
LID - 10.1093/rheumatology/kev001 [doi]
AB  - OBJECTIVE: To assess drug survival and the reasons for switching anti-TNF-alpha 
      therapy in SpA patients in a Spanish nationwide study. METHODS: A cross-sectional 
      study was performed. Sample size was calculated to represent all regions and 
      hospitals throughout the country. Demographic data, patient characteristics and 
      disease activity parameters were obtained. Drug survival and reasons for 
      switching anti-TNF therapy were also recorded. RESULTS: A total of 467 SpA 
      patients receiving at least one anti-TNF agent were identified. Among patients 
      who received a first, second and third anti-TNF course, 39.4%, 37.4% and 23.1% 
      discontinued treatment, respectively. The main reasons for switching anti-TNF 
      agents in the first course were lack or loss of efficacy (LOE) and adverse events 
      (AEs) in 40% and 30% of switchers, respectively. Similarly, reasons for switching 
      during the second anti-TNF course were LOE in 48% and AEs in 28% of switchers. Of 
      the 467 SpA patients starting anti-TNF therapy, 28% switched to a second and 8% 
      switched to a third therapy. Mean drug survival for the first, second and third 
      anti-TNF courses were 84.4 (95% CI 78.4, 90.5), 70.2 (95% CI 61.6, 78.9) and 64.8 
      (95% CI 51.1, 78.5) months, respectively (P = 0.315). CONCLUSION: Twenty-eight 
      per cent of SpA patients starting anti-TNF therapy switched to a second anti-TNF 
      agent. Drug survival did not differ among anti-TNF courses. The main reason for 
      switching anti-TNF therapy was LOE. Switchers were more frequently women and had 
      higher disease activity parameters at the time of the study than non-switchers.
CI  - (c) The Author 2015. Published by Oxford University Press on behalf of the British 
      Society for Rheumatology. All rights reserved. For Permissions, please email: 
      journals.permissions@oup.com.
FAU - Rosales-Alexander, Jose Luis
AU  - Rosales-Alexander JL
AD  - Rheumatology Department, 'Hospiten Rambla', Santa Cruz de Tenerife, 
      jose_rosales37@hotmail.com.
FAU - Balsalobre Aznar, Jeronimo
AU  - Balsalobre Aznar J
AD  - Rheumatology Department, 'Hospiten Rambla', Santa Cruz de Tenerife.
FAU - Perez-Vicente, Sabina
AU  - Perez-Vicente S
AD  - Research Unit, Spanish Society of Rheumatology, Madrid and.
FAU - Magro-Checa, Cesar
AU  - Magro-Checa C
AD  - Rheumatology Department, San Cecilio University Hospital, Granada, Spain.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150312
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Substitution/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Spain/epidemiology
MH  - Spondylarthropathies/diagnosis/*drug therapy/epidemiology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
OTO - NOTNLM
OT  - anti-tumour necrosis factor alpha
OT  - biologic therapy
OT  - spondyloarthropathies
OT  - switch
EDAT- 2015/03/15 06:00
MHDA- 2015/10/03 06:00
CRDT- 2015/03/14 06:00
PHST- 2014/04/22 00:00 [received]
PHST- 2015/03/14 06:00 [entrez]
PHST- 2015/03/15 06:00 [pubmed]
PHST- 2015/10/03 06:00 [medline]
AID - kev001 [pii]
AID - 10.1093/rheumatology/kev001 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2015 Aug;54(8):1459-63. doi: 10.1093/rheumatology/kev001. 
      Epub 2015 Mar 12.